Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections
Abstract
Aim: Compare clinical and cost outcomes associated with ceftaroline fosamil with other commonly used antibiotics in complicated skin and soft tissue infections. Methods: Retrospective analysis of hospital records from 2010 to 2013 in Premier’s Perspective comparative database for adults with complicated skin and soft tissue infection treated with intravenous ceftaroline fosamil, vancomycin, daptomycin, linezolid or tigecycline. Length of stay, inpatient costs and mortality were compared between propensity score-matched treatment groups. Results & conclusion: Compared with the other commonly used antibiotics, matched patients in the ceftaroline fosamil treatment group had an equivalent (1%) or lower (compared with linezolid, 2%) in-hospital mortality rate, and significantly lower (p < 0.001) average unadjusted and regression-adjusted length of stay and inpatient costs (savings of $3398.80 compared with daptomycin).
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest
1.
Pollack CV, Amin A, Ford WT et al. Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. J. Emerg. Med. 48(4), 508–519 (2015).
2.
Dryden MS. Complicated skin and soft tissue infection. J. Antimicrob. Chemother. 65(Suppl. 3), iii35–iii44 (2010).
3.
Chambers HF. Pharmacology and the treatment of complicated skin and skin-structure infections. N. Engl. J. Med. 370(23), 2238–2239 (2014).
4.
Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41(10), 1373–1406 (2005).
5.
Gould IM, David MZ, Esposito S et al. New insights into methicillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int. J. Antimicrob. Agents. 39(2), 96–104 (2012).
• Reviews recent literature on the rise in methicillin-resistant Staphylococcus aureus resistance to newer antibiotics.
6.
Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9(6), 1065–1078 (1987).
7.
Boyce JM, Landry M, Deetz TR, DuPont HL. Epidemiologic studies of an outbreak of nosocomial methicillin-resistant Staphylococcus aureus infections. Infect. Control. 2(2), 110–116 (1981).
8.
Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis. 36(5), 592–598 (2003).
• Highlights the treatment costs associated with methicillin-resistant Staphylococcus aureus compared with methicillin-susceptible Staphylococcus aureus.
9.
Rubinstein E, Keynan Y. Vancomycin revisited – 60 years later. Front. Public Heal. 2, 217 (2014).
10.
Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (’the MIC Creep’): implications for therapy. F1000 Med. Rep. 4, 4 (2012).
11.
European Medicines Agency. Assessment report for ceftaroline fosamil. Procedure No.: EMEA/H/C/002252 (2012). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002252/WC500132587.pdf
12.
Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl. 4), iv41–iv51 (2010).
13.
Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J. Antimicrob. Chemother. 65(Suppl. 4), iv53–iv65 (2010).
14.
Dryden M, Wilson D, Iaconis J, Gonzalez J. A Phase III trial of ceftaroline fosamil 600 mg q8h versus vancomycin plus aztreonam in patients with cSSTI with systemic inflammatory response or underlying comorbidities. In: European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark, 25–28 April 2015.
15.
Corey GR, Wilcox M, Talbot GH et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin. Infect. Dis. 51(6), 641–650 (2010).
16.
Santos PD, Davis A, Jandourek A, Smith A, David Friedland H. Ceftaroline fosamil and treatment of acute bacterial skin and skin structure infections: CAPTURE study experience. J. Chemother. 25(6), 341–346 (2013).
• This was the first study to demonstrate real-world efficacy of ceftaroline fosamil treatment of complicated skin and skin structure infections (cSSTIs).
17.
Guervil DJ, Kaye KS, Hassoun A, Cole P, Huang X-Y, Friedland HD. Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP). J. Chemother. doi:1973947815Y0000000010 (2015) (Epub ahead of print).
18.
Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J. Clin. Epidemiol. 61(12), 1234–1240 (2008).
19.
Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 10(2), 150–161 (2011).
20.
Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg. Infect. (Larchmt). 6(3), 283–295 (2005).
21.
Nathwani D, Moitra S, Dunbar J, Crosby G, Peterkin G, Davey P. Skin and soft tissue infections: development of a collaborative management plan between community and hospital care. Int. J. Clin. Pract. 52(7), 456–460 (1998).
22.
Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev. Anti. Infect. Ther. 6(5), 751–763 (2008).
23.
Marton JP, Jackel JL, Carson RT, Rothermel CD, Friedman M, Menzin J. Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims. Curr. Med. Res. Opin. 24(10), 2821–2828 (2008).
24.
Suaya Ja, Mera RM, Cassidy A et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect. Dis. 14(1), 296 (2014).
25.
Muszbek N, Chapman R, Browne C et al. Using daptomycin in hospitalised patients with cSSTI caused by Staphylococcus aureus has an impact on costs. Chemotherapy 59(6), 427–434 (2013).
26.
Zervos MJ, Freeman K, Vo L et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J. Clin. Microbiol. 50(2), 238–245 (2011).
27.
Garau J, Ostermann H, Medina J, Avila M, McBride K, Blasi F. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin. Microbiol. Infect. 19(9), E377–E385 (2013).
Information & Authors
Information
Published In
Copyright
© AstraZeneca plc.
History
Published online: 1 March 2016
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections. (2016) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2015-0024
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Tristan Ferry, Charalambos Gogos, Alex Soriano, Francesco Blasi, Wajeeha Ansari, Michal Kantecki, Bernd Schweikert, Gustavo Luna, Matteo Bassetti, Real-World Use and Treatment Outcomes of Ceftaroline Fosamil in Patients with Complicated Skin and Soft Tissue Infection: A Multinational Retrospective Study, Infection and Drug Resistance, 10.2147/IDR.S455515, Volume 17, (2773-2783), (2024).
- Konstantinos Leventogiannis, Maria Mouktaroudi, Evangelos J. Giamarellos-Bourboulis, Clinical evidence supporting ceftaroline fosamil and ceftobiprole for complicated skin and soft tissue infections, Current Opinion in Infectious Diseases, 10.1097/QCO.0000000000000900, 36, 2, (89-94), (2023).
- Antoni Torres, Alex Soriano, Simone Rivolo, Edit Remak, Carmen Peral, Michal Kantecki, Wajeeha Ansari, Claudie Charbonneau, Jennifer Hammond, Santiago Grau, Mark Wilcox, Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System, ClinicoEconomics and Outcomes Research, 10.2147/CEOR.S329494, Volume 14, (149-161), (2022).
- Kaiwen Chen, On the Treatment of MRSA Skin and Soft Tissue Infection with Ceftaroline and Linezolid, Proceedings of the 2nd International Symposium on Artificial Intelligence for Medicine Sciences, 10.1145/3500931.3500988, (322-329), (2021).
- S. S. Almarzoky Abuhussain, K. J. Goodlet, M. D. Nailor, D. P. Nicolau, Optimizing skin and skin structure infection outcomes: considerations of cost of care, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1080/14737167.2018.1450142, 18, 3, (235-244), (2018).
- Laura Dormer, Introducing Volume 6 of the Journal of Comparative Effectiveness Research , Journal of Comparative Effectiveness Research, 10.2217/cer-2016-0074, 6, 1, (1-3), (2016).